Main Management ETF Advisors LLC Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Main Management ETF Advisors LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,696 shares of the biotechnology company’s stock after selling 512 shares during the period. Main Management ETF Advisors LLC’s holdings in Ascendis Pharma A/S were worth $784,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Rice Hall James & Associates LLC grew its holdings in Ascendis Pharma A/S by 2.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock worth $22,562,000 after acquiring an additional 3,274 shares in the last quarter. abrdn plc lifted its position in shares of Ascendis Pharma A/S by 18.3% in the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock worth $25,769,000 after purchasing an additional 28,967 shares during the period. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 540.5% during the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 427 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Ascendis Pharma A/S by 14.0% during the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock valued at $28,151,000 after buying an additional 25,164 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at approximately $1,725,000.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday. Wedbush lifted their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Finally, Morgan Stanley upgraded shares of Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $180.00 to $250.00 in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $216.07.

Ascendis Pharma A/S Trading Up 4.6%

Shares of Ascendis Pharma A/S stock opened at $161.52 on Wednesday. The firm’s 50 day simple moving average is $156.29 and its two-hundred day simple moving average is $141.85. The firm has a market capitalization of $9.85 billion, a price-to-earnings ratio of -22.75 and a beta of 0.41. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analysts’ expectations of $98.56 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.